Clinical Trials

  • Principal Investigator:

    Ronald J. Wapner, MD
    This research study is being done to is to understand how CPAP for sleep apnea may affect hypertensive disorders of pregnancy and other complications of pregnancy such as gestational diabetes. The purpose of the home sleep test is to find women with sleep apnea. Sleep apnea is when you have one or more pauses in breathing or shallow breaths while you sleep. Studies have shown that women with sleep apnea have an increased risk of high blood pressure and diabetes during pregnancy. If the test shows that you have sleep apnea in the mild to moderate range you will be eligible for a research study...
  • Principal Investigator:

    Carolyn L. Westhoff, MD
    Did you have unprotected sex? Do you weigh at least 176 pounds? This clinical trial is an experimental research study using a new dose of emergency contraception or morning-after pill. You may qualify if you: Are a premenopausal, healthy woman between the ages of 18 and 40. Weigh more than 176 pounds. Have an intact uterus with at least one ovary. Have regular menstrual cycles. If you qualify, you will: Receive a free investigational emergency contraceptive pill. Comply with protocol requirements, including taking an oral medication. Attend approximately 2 clinic visits and receive follow up...
  • Principal Investigator:

    Carolyn L. Westhoff, MD
    Did you have unprotected sex? Do you weigh at least 176 pounds? This clinical trial is an experimental research study using a new dose of emergency contraception or morning-after pill. You may qualify if you: Are a premenopausal, healthy woman between the ages of 18 and 40. Weigh more than 176 pounds. Have an intact uterus with at least one ovary. Have regular menstrual cycles. If you qualify, you will: Receive a free investigational emergency contraceptive pill. Comply with protocol requirements, including taking an oral medication. Attend approximately 2 clinic visits and receive follow up...
  • Principal Investigator:

    June Y. Hou, MD
    The purpose of the first part of this study, the Dose Escalation part, is to study and identify the highest tolerable safe dose of MORAb-202. The purpose of the Expansion part is to further investigate how the different tumor types being studied respond to the study drug and to gather more information on its safety and effectiveness. This study will enroll patients with triple-negative breast cancer (TNBC), endometrial cancer (EC), non-small cell lung cancer (NSCLC, adenocarcinoma), primary peritoneal cancer or fallopian tube cancer, and ovarian cancer. If it is determined that you meet all...
  • Principal Investigator:

    Carolyn L. Westhoff, MD
    If you are a woman between the ages of 18 and 35, are pre-menopausal, sexually active and do NOT wish to become pregnant, you are invited to see if you may qualify for a research study. The purpose of this research study is to test the effectiveness of an investigational oral birth control pill. If you qualify, you will receive investigational study medication, study-related medical exams, and laboratory services at no charge. You may also be reimbursed for time, travel, and other expenses.
  • Principal Investigator:

    S. Zev Williams, MD, PhD
    Researchers at the Columbia University Fertility Center (CUFC) have collaborated with Princeton to learn more about the changes that occur infertility as women get older. We are looking for women between the ages of 20 and 50 who are not pregnant. The study involves a one time blood draw (3 small tubes) and a questionnaire. Visits take less than an hour. All participants will receive $50.
  • Principal Investigator:

    Jason D. Wright, MD
    HE4 (Human Epididymis Protein 4) is a biomarker expressed in the normal lining of the female genital tract and breast. We are doing this research study to if HE4 is an indicator of treatment response during initial therapy for Primary Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancers. For this we will collect blood at specific intervals. You are being asked to take part in this study because you have been diagnosed with Primary Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer and will be receiving initial treatment for your disease.
  • Principal Investigator:

    June Y. Hou, MD
    The main purpose of this study is to: Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or in combination with cemiplimab to research subjects with ovarian cancer without too many side effects. The study will also look at the levels of REGN4018 and/or cemiplimab in the body and measure how well your body can remove the study drug(s). This is called pharmacokinetics. The study will also look at any signs that REGN4018 alone or with cemiplimab can treat cancer.
  • Principal Investigator:

    June Y. Hou, MD
    We are doing this study to find out if tisotumab vedotin treats ovarian cancer. We want to see if patients with your kind of ovarian cancer respond to the drug. We want to see how long it takes patients to respond to tisotumab vedotin and how long the response lasts. We also want to learn more about any side effects patients have when they get tisotumab vedotin. Tisotumab vedotin is a type of drug called an antibody drug conjugate or ADC. ADCs usually have 2 parts. Antibody: Antibodies are part of your immune system. Usually, they help protect you from getting sick. In tisotumab vedotin, we...
  • Principal Investigator:

    Catherine Monk, PHD
    Do you ever wish there was more information on how to handle the challenges of pregnancy and having a new baby? This study looks into whether certain behavioral techniques used by mothers can help their babies sleep more and cry less and, in turn, improve womens moods and child outcomes. The study starts when you are in your third trimester of pregnancy and lasts until your baby is about 4 months old. After you attend a virtual screening session by phone or video to determine that you are fully eligible for the study, you will have 4 virtual sessions by phone or video; 1) at 28-32 weeks of...

Pages